MedPath

Local Host Modulating Agents Alendronate & Aloe Vera for Treatment of Furcation Defects in Chronic Periodontitis

Phase 2
Completed
Conditions
Chronic Periodontitis
Interventions
Registration Number
NCT03204097
Lead Sponsor
Government Dental College and Research Institute, Bangalore
Brief Summary

Alendronate (ALN), commonly use bisphosphonates is proposed to have osteostimulative properties in vivo and in vitro, as shown by an increase in the matrix formation, and acts as a potent inhibitor of bone resorption. AV widely known for its wound healing, analgesic, antioxidant, antibacterial, antiviral, antifungal, immune boosting and significant anti-inflammatory properties. The present study aims to explore the efficacy of 1% ALN and AV gel as a local drug delivery as an adjunct to scaling and root planing (SRP) for the treatment of degree II furcation defects

Detailed Description

Alendronate (ALN), commonly use bisphosphonates is proposed to have osteostimulative properties in vivo and in vitro, as shown by an increase in the matrix formation, and acts as a potent inhibitor of bone resorption. AV widely known for its wound healing, analgesic, antioxidant, antibacterial, antiviral, antifungal, immune boosting and significant anti-inflammatory properties. The present study aims to explore the efficacy of 1% ALN and AV gel as a local drug delivery as an adjunct to scaling and root planing (SRP) for the treatment of degree II furcation defects.

Methods: Ninety patients with mandibular buccal class II furcation defects were randomly allocated into three treatment groups: SRP plus placebo gel (group 1), SRP plus 1% ALN gel (group 2) and SRP plus AV gel (group3). Clinical and radiographic parameters were recorded at baseline and gel were delivered at respective site. Then again all clinical and radiographic parameters were recorded after 6 and 12 months from baseline.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
90
Inclusion Criteria

Systemically healthy patients with mandibular class II furcation defects and asymptomatic endodontically vital mandibular molars with radiolucency in furcation area with PD ≥ 5mm and horizontal PD ≥ 3mm and with no history of antibiotic or any periodontal therapy in past 6 months were included in the study -

Exclusion Criteria

Subjects with any known systemic disease, allergic to alendronate or aloe vera, on systemic alendronate therapy, alcoholics, tobacco users, pregnant or lactating women

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
group 1placeboScaling and root planing (SRP) followed by placebo gel local drug delivery
group 2AlendronateSRP followed by 1% Alendronate (ALN) gel
group 3Aloe VeraSRP followed by Aloevera (AV) gel
Primary Outcome Measures
NameTimeMethod
Change in Bone defect depthbaseline, 6 & 12 months

Assessed in percentage

Secondary Outcome Measures
NameTimeMethod
Change in modified sulcus bleeding indexbaseline, 6 & 12 months

scale 0-3

Change in relative vertical clinical attachment levelbaseline, 6 & 12 months

measured in mm

Change in pocket probing depthbaseline, 6 & 12 months

measured in mm

Change in Plaque indexbaseline, 6 & 12 months

scale 0-3

Change in relative horizontal clinical attachment levelbaseline, 6 & 12 months

measured in mm

© Copyright 2025. All Rights Reserved by MedPath